Harbour Bio Starts China Phase III Trial of Novel Dry Eye Treatment
March 15, 2021 at 05:07 AM EDT
Harbour BioMed has dosed the first patient in the China arm of a global Phase III trial of a novel treatment for moderate-to-severe dry eye disease (DED). Tanfanercept (HBM9036) is a tumor necrosis factor (TNF) receptor-1 fragment-based anti-inflammatory biologic. In 2017, Harbour in-licensed greater China rights to Tanfanercept from South Korea 's HanAll Biopharma (KS: 009420) in a two-drug $81 million agreement. The other candidate in the HanAll agreement is an IgG-mediated molecule also aimed at autoimmune diseases. Harbour is a US-Netherlands-Shanghai biopharma. More details.... Stock Symbol: (HK: 02142) Share this with colleagues: // //
